Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion
WSJ·2026-01-10 03:58

公司业务与研发管线 - Revolution公司正在开发针对癌症分子驱动因子的药物 [1] 行业技术趋势 - 癌症治疗领域正聚焦于针对特定分子驱动因子的精准疗法开发 [1]

Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion - Reportify